March 2004

Cardiovascular Agents

Caduet (amlodipine/atorvastatin) Tablets

Manufacturer: Pfizer Inc.

Drug Approval Classification: Original New Drug Application (Approval Date: 01/30/04)

Indication: This new drug application provides for the use of Caduet (amlodipine besylate/atorvastatin calcium) in patients for whom treatment with both amlodipine and atorvastatin is appropriate as indicated.

Amlodipine is indicated for the treatment of: Hypertension, Chronic stable angina, and Vasospastic angina (Prinzmetal's or variant angina). Atorvastatin is indicated for the treatment of: Heterozygous familial and nonfamilial hypercholesterolemia, Elevated serum triglyceride (TG) levels, Primary dysbetalipoproteinemia, Homozygous familial hypercholesterolemia, and Boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia.

Dosing: Caduet tablets contain amlodipine besylate and atorvastatin calcium equivalent to amlodipine and atorvastatin in the dose strengths described below:

Tablet Strength (amlodipine besylate/ atorvastatin calcium) mg:

5/40 5/80 10/40 10/80 5/10 5/20 10/10 10/20

Caduet (amlodipine/atorvastatin) Tablets Labeling

Medscape Pharmacists. 2004;5(1) © 2004  Medscape

Cite this: March 2004 - Medscape - Apr 06, 2004.